Joyce Danter
Gerontology · Dallas, TXNPI 1992737480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 703 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 703 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$921
- Lilly USA, LLC$808
- AstraZeneca$680
- Bausch Health US, LLC$678
- Kowa Pharmaceuticals America, Inc.$668
- plus $5K from 40 others
What the payments were for
- Food & beverage$10,135100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,137 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 65 | $74,974 |
| OzempicSemaglutide | 54 | $52,903 |
| FarxigaDapagliflozin Propanediol | 49 | $48,180 |
| TrulicityDulaglutide | 22 | $24,408 |
| RybelsusSemaglutide | 12 | $23,267 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,483 |
| UnithroidLevothyroxine Sodium | 131 | $8,680 |
| BelsomraSuvorexant | 14 | $6,001 |
| SynthroidLevothyroxine Sodium | 29 | $3,385 |
| Liothyronine Sodium | 91 | $2,364 |
| ProgesteroneProgesterone, Micronized | 45 | $2,017 |
| ValacyclovirValacyclovir Hcl | 33 | $1,638 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $1,429 |
| Atorvastatin Calcium | 164 | $1,384 |
| Gabapentin | 99 | $1,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $808 | $99,38387 claims |
| Novo NordiskOzempic, Rybelsus | $921 | $76,17066 claims |
| AstraZenecaFarxiga | $680 | $48,18049 claims |
| GSKTrelegy Ellipta | $189 | $21,48321 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $408 | $9,216186 claims |
| MerckBelsomra | $236 | $6,00114 claims |
| AbbVieSynthroid, Armour Thyroid | $1,521 | $4,49541 claims |
| PfizerPaxlovid | $290 | $1,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.
Other gerontology in Dallas
- Tiffany KesslerDallas$84K
- Marissa Marti-SmithDallas$27K
- Monique BrumseyDallas$6K
- Sheila BehimehrDallas$6K
- Angela ThomasDallas$5K
- Kristen EusebeDallas$5K
- Jessica ScarfDallas$4K
- Kimberly McHughDallas$4K
- Kimberly WelchCoppell$113K
- Jennifer WestFort Worth$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.